AMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection)
December 14, 2020 08:47 ET
|
AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. has submitted its response to the FDA’s Notice of Opportunity for a Hearing (“NOOH”) regarding the Agency’s proposal to...
AMAG Pharmaceuticals Requests Hearing to Maintain Makena® (Hydroxyprogesterone Caproate Injection) as a Treatment Option for Clinically Indicated Pregnant Patients
October 14, 2020 16:11 ET
|
AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug...
Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals
October 01, 2020 10:45 ET
|
AMAG Pharmaceuticals, Inc.
Addition of AMAG’s category leading treatments positions Covis to become a global market leader of therapeutic solutions for life-threatening conditions and chronic illnesses Covis will commence a...
AMAG Pharmaceuticals to Participate in H.C. Wainwright 22nd Annual Global Investment Conference
September 09, 2020 08:00 ET
|
AMAG Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Scott Myers, Chief Executive Officer, and Brian Piekos, Chief Financial Officer,...